The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Anti-TNF Therapy in Crohn’s Disease
Open accessAbstract
Crohn’s disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is increasing including younger or childhood-onset of disease. The natural history of Crohn’s disease is characterized by a remitting and relapsing course that progresses to complications and surgery in most patients. The goals of treatment are to achieve clinical and endoscopic remission, to avoid disease progression and minimise surgical resections. Medical treatment usually features antibiotics, corticosteroids, immunomodulators (thiopurines, methotrexate). Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn’s disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. There are significant considerations that need to be borne in mind, when treating patients including immunogenicity, safety profile and duration of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.001 · Cited by 4,833
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,176
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Leukocyte-endothelial adhesion molecules
Carlos, T., & Harlan, J. (1994) · Blood · doi:10.1182/blood.v84.7.2068.2068 · Cited by 2,701
Torres, J., Mehandru, S., Colombel, J.-F., & Peyrin-Biroulet, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31711-1 · Cited by 2,682
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Colombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Gomollón, F., Dignass, A., Annese, V., Tilg, H., Van Assche, G., Lindsay, J. O., Peyrin-Biroulet, L., Cullen, G. J., Daperno, M., Kucharzik, T., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw168 · Cited by 2,057
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Kindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
van Dullemen, H. M., van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., & Woody, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90277-5 · Cited by 1,084
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Rahier, J. F., Magro, F., Abreu, C., Armuzzi, A., Ben-Horin, S., Chowers, Y., Cottone, M., de Ridder, L., G., D., Ehehalt, R., et al. (2014) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2013.12.013 · Cited by 923
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
Lichtenstein, G. R., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Diamond, R. H., Chen, D. M., Pritchard, M. L., & Sandborn, W. J. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.002 · Cited by 905
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Two tumour necrosis factor receptors: structure and function
Vandenabeele, P., Declercq, W., Beyaert, R., & Fiers, W. (1995) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)89088-1 · Cited by 799
D'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., & Rutgeerts, P. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 745
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Role of cytokines in inflammatory bowel disease
Sanchez-Muñoz, F., Dominguez-Lopez, A., & Yamamoto-Furusho, J. K. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4280 · Cited by 699
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
Cancers Complicating Inflammatory Bowel Disease
Beaugerie, L., & Itzkowitz, S. H. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403718 · Cited by 678
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Gisbert, J. P., & Panés, J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.88 · Cited by 664
Maser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.73 · Cited by 604
Louis, E., Mary, J., Vernier–Massouille, G., Grimaud, J., Bouhnik, Y., Laharie, D., Dupas, J., Pillant, H., Picon, L., Veyrac, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.09.034 · Cited by 597
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Rutgeerts, P., Van Assche, G., Sandborn, W. J., Wolf, D. C., Geboes, K., Colombel, J., Reinisch, W., Kumar, A., Lazar, A., Camez, A., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.035 · Cited by 580
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Feuerstein, J. D., Nguyen, G. C., Kupfer, S. S., Falck-Ytter, Y., Singh, S., Gerson, L., Hirano, I., Nguyen, G. C., Rubenstein, J. H., Smalley, W. E., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.032 · Cited by 576
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.155812 · Cited by 535
Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease
Long, M. D., Martin, C. F., Pipkin, C. A., Herfarth, H. H., Sandler, R. S., & Kappelman, M. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.004 · Cited by 526
Murch, S. H., Braegger, C. P., Walker-Smith, J. A., & MacDonald, T. T. (1993) · Gut · doi:10.1136/gut.34.12.1705 · Cited by 520
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Tumour necrosis factor and Crohn's disease.
Van Deventer, S. J. (1997) · Gut · doi:10.1136/gut.40.4.443 · Cited by 500
Murch, S. H., Lamkin, V. A., Savage, M. O., Walker-Smith, J. A., & MacDonald, T. T. (1991) · Gut · doi:10.1136/gut.32.8.913 · Cited by 482
Nesbitt, A., Fossati, G., Bergin, M., Stephens, P., Stephens, S., Foulkes, R., Brown, D., Robinson, M., & Bourne, T. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20225 · Cited by 477
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
Fidder, H., Schnitzler, F., Ferrante, M., Noman, M., Katsanos, K., Segaert, S., Henckaerts, L., Van Assche, G., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.163642 · Cited by 449
Billioud, V., Sandborn, W. J., & Peyrin-Biroulet, L. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.60 · Cited by 433
Amiri, P., Locksley, R. M., Parslow, T. G., Sadickt, M., Rector, E., Ritter, D., & McKerrow, J. H. (1992) · Nature · doi:10.1038/356604a0 · Cited by 419
Adalimumab for the treatment of fistulas in patients with Crohn’s disease
Colombel, J.-F., Schwartz, D. A., Sandborn, W. J., Kamm, M. A., D’Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., et al. (2009) · Gut · doi:10.1136/gut.2008.159251 · Cited by 365
Sands, B. E., Blank, M. A., Patel, K., & Van Deventer, S. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00414-8 · Cited by 359
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Gisbert, J. P., Marín, A. C., McNicholl, A. G., & Chaparro, M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13083 · Cited by 323
Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N. (2018) · Cytokine · doi:10.1016/j.cyto.2016.08.014 · Cited by 316
Tumour-necrosis-factor antibody treatment in Crohn's disease
Derkx, B., Taminiau, J., Radema, S., Stronkhorst, A., Wortel, C., Tytgat, G., & van Deventer, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)91375-v · Cited by 308
Yarur, A. J., Kanagala, V., Stein, D. J., Czul, F., Quintero, M. A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13970 · Cited by 308
D’Haens, G., Vermeire, S., Lambrecht, G., Baert, F., Bossuyt, P., Pariente, B., Buisson, A., Bouhnik, Y., Filippi, J., vander Woude, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.004 · Cited by 305
Eissner, G., Kolch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 298
Dassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.031 · Cited by 295
Andersen, N. N., Pasternak, B., Basit, S., Andersson, M., Svanström, H., Caspersen, S., Munkholm, P., Hviid, A., & Jess, T. (2014) · JAMA · doi:10.1001/jama.2014.5613 · Cited by 273
Kane, S. V., & Acquah, L. A. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.71 · Cited by 267
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
Danese, S., Fiorino, G., Raine, T., Ferrante, M., Kemp, K., Kierkus, J., Lakatos, P. L., Mantzaris, G., van der Woude, J., Panes, J., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw198 · Cited by 248
Yarur, A. J., Jain, A., Sussman, D. A., Barkin, J. S., Quintero, M. A., Princen, F., Kirkland, R., Deshpande, A. R., Singh, S., & Abreu, M. T. (2016) · Gut · doi:10.1136/gutjnl-2014-308099 · Cited by 242
Torres, J., Boyapati, R. K., Kennedy, N. A., Louis, E., Colombel, J.-F., & Satsangi, J. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.055 · Cited by 225
Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability.
Mullin, J. M., & Snock, K. V. (1990) · PubMed · Cited by 217
Singh, S., Nagpal, S. J. S., Murad, M. H., Yadav, S., Kane, S. V., Pardi, D. S., Talwalkar, J. A., & Loftus, E. V. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.033 · Cited by 210
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207
Kuijpers, T. W., Hakkert, B. C., Hart, M. H., & Roos, D. (1992) · The Journal of cell biology · doi:10.1083/jcb.117.3.565 · Cited by 203
Stidham, R. W., Lee, T. C. H., Higgins, P. D. R., Deshpande, A. R., Sussman, D. A., Singal, A. G., Elmunzer, B. J., Saini, S. D., Vijan, S., & Waljee, A. K. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12749 · Cited by 201
Eissner, G., Kirchner, S., Lindner, H., Kolch, W., Janosch, P., Grell, M., Scheurich, P., Andreesen, R., & Holler, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6193 · Cited by 193
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.031 · Cited by 175
Van den Brande, J. M. H., Koehler, T. C., Zelinkova, Z., Bennink, R. J., te Velde, A. A., ten Cate, F. J. W., van Deventer, S. J. H., Peppelenbosch, M. P., & Hommes, D. W. (2007) · Gut · doi:10.1136/gut.2006.105379 · Cited by 170
O’Meara, S., Nanda, K. S., & Moss, A. C. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000436951.80898.6d · Cited by 160
Sandborn, W. J., Abreu, M. T., D’Haens, G., Colombel, J., Vermeire, S., Mitchev, K., Jamoul, C., Fedorak, R. N., Spehlmann, M. E., Wolf, D. C., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.04.021 · Cited by 152
Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohnʼs perianal fistulas
Tozer, P. J., Ng, S. C., Siddiqui, M. R. S., Plamondon, S., Burling, D. N., Gupta, A., Swatton, A., Tripoli, S., Vaizey, C. J., Kamm, M. A., et al. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21940 · Cited by 146
Self-citationUpdate on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease
Cohen, B. L., & Sachar, D. B. (2017) · BMJ · doi:10.1136/bmj.j2505 · Cited by 146
Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study
Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., Rizzello, F., Castiglione, F., Benazzato, L., Papi, C., et al. (2005) · Gut · doi:10.1136/gut.2005.075937 · Cited by 143
Targeting TNF-α for the treatment of inflammatory bowel disease
Billiet, T., Rutgeerts, P. J., Ferrante, M., Assche, G. V., & Vermeire, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.858695 · Cited by 140
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease
Akobeng, A. K., & Zachos, M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003574.pub2 · Cited by 139
Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions
Bègue, B., Wajant, H., Bambou, J., Dubuquoy, L., Siegmund, D., Beaulieu, J., Canioni, D., Berrebi, D. D., Brousse, N., Desreumaux, P., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.022 · Cited by 135
Harashima, S., Horiuchi, T., Hatta, N., Morita, C., Higuchi, M., Sawabe, T., Tsukamoto, H., Tahira, T., Hayashi, K., Fujita, S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.130 · Cited by 131
Adalimumab safety in global clinical trials of patients with Crohnʼs disease
Colombel, J., Sandborn, W. J., Panaccione, R., Robinson, A. M., Lau, W., Li, J., & Cardoso, A. T. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20956 · Cited by 127
Paleolog, E. M., Delasalle, S., Buurman, W. A., & Feldmann, M. (1994) · Blood · doi:10.1182/blood.v84.8.2578.2578 · Cited by 109
Lichtenstein, G. R., Thomsen, O. Ø., Schreiber, S., Lawrance, I. C., Hanauer, S. B., Bloomfield, R., & Sandborn, W. J. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.01.014 · Cited by 109
Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events
Hansen, R. A., Gartlehner, G., Powell, G. E., & Sandler, R. S. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.016 · Cited by 108
Miehsler, W., Novacek, G., Wenzl, H., Vogelsang, H., Knoflach, P., Kaser, A., Dejaco, C., Petritsch, W., Kapitan, M., Maier, H., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.001 · Cited by 106
Casteele, N. V., & Gils, A. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.374 · Cited by 101
Developing a core outcome set for fistulising perianal Crohn’s disease
Sahnan, K., Tozer, P. J., Adegbola, S. O., Lee, M. J., Heywood, N., McNair, A., Hind, D., Yassin, N., Lobo, A., Brown, S. R., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315503 · Cited by 93
Self-citationWaugh, A. W. G., Garg, S., Matic, K., Gramlich, L. M., Wong, C. K. W., Sadowski, D. C., Millan, M., Bailey, R. J., Todoruk, D., Cherry, R. D., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04446.x · Cited by 90
Kestens, C., van Oijen, M. G. H., Mulder, C. L. J., Bodegraven, A. A. V., Dijkstra, G. D. H., de Jong, D., Ponsioen, C. Y., van Tuyl, B. A. C., Siersema, P. D., Fidder, H. H., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.01.012 · Cited by 87
Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future
Berns, M. S., & Hommes, D. W. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1126247 · Cited by 68
Yarur, A. J., & Rubin, D. T. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000380 · Cited by 66
Genotypes and phenotypes in Crohn’s disease: do they help in clinical management?
Gasché, C., & Grundtner, P. (2004) · Gut · doi:10.1136/gut.2003.035600 · Cited by 64
Anti-TNF agents in Crohn’s disease
Assche, G. V., & Rutgeerts, P. J. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.1.103 · Cited by 64
Rutgeerts, P. J., Schreiber, S., Feagan, B. G., Keininger, D. L., O’Neil, L., Fedorak, R. N., & CDP870 Crohn’s Disease Study Group (2007) · International Journal of Colorectal Disease · doi:10.1007/s00384-007-0395-7 · Cited by 57
Top-Down or Step-Up Treatment in Crohn's Disease?
Rogler, G. (2013) · Digestive Diseases · doi:10.1159/000347190 · Cited by 57
Serum sickness, encephalitis and other complications of anti-cytokine therapy
Vermeire, S., Assche, G. V., & Rutgeerts, P. J. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2008.12.005 · Cited by 51
Dai, C., Liu, W., Jiang, M., & Sun, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110797 · Cited by 50
Steenholdt, C., Palarasah, Y., Bendtzen, K., Teisner, A., Brynskov, J., Teisner, B., & Nielsen, C. H. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12330 · Cited by 48
Infliximab in the treatment of Crohn's disease
Poggioli, G., Laureti, S., Campieri, M., Pierangeli, F., Gionchetti, P., Ugolini, F., Gentilini, L., Bazzi, P., Rizzello, F., & Coscia, M. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.2.301 · Cited by 43
Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)
Feuerstein, J. D., & Cheifetz, A. S. (2014) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2014.05.002 · Cited by 40
Medical and surgical management of perianal Crohn’s disease
Adegbola, S. O. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0236 · Cited by 32
Self-citationComparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice
Patil, S. A., Rustgi, A., LANGENBERG, P. W., & Cross, R. K. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2323-0 · Cited by 22
Hart, A. L., & Ng, S. C. (2015) · Medicine · doi:10.1016/j.mpmed.2015.02.006 · Cited by 21
Self-citationAnti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?
Oikonomopoulos, A., van Deen, W. K., & Hommes, D. W. (2013) · Current Drug Targets · doi:10.2174/13894501113149990164 · Cited by 20
Bau, M., Zacharias, P., Ribeiro, D. A., Boaron, L., Filho, Á. S., & Kotze, P. G. (2017) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.201700000-43 · Cited by 17
Safety considerations when using anti-TNFα therapy to treat Crohn’s disease
Pagnini, C., Arseneau, K. O., & Cominelli, F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.976610 · Cited by 10
Cited by
Stojanov, S., Berlec, A., & Štrukelj, B. (2020) · Microorganisms · doi:10.3390/microorganisms8111715 · Cited by 1,885
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Webster, J. D., & Vucic, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00365 · Cited by 316
Seoane-Viaño, I., Gómez-Lado, N., Lázare-Iglesias, H., Rey-Bretal, D., Lamela-Gómez, I., Otero-Espinar, F. J., Blanco-Méndez, J., Antúnez-López, J. R., Pombo-Pasín, M., Aguiar, P., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118713 · Cited by 24
Metadata
- Authors
- Adegbola, S. O., Sahnan, K., Warusavitarne, J., Hart, A., & Tozer, P.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-07-31
- Volume
- 19
- Issue
- 8
- Pages
- 2244
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2887951414
- Cited by
- 274
- References
- 112
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.